Patents by Inventor Meinrad Gawaz
Meinrad Gawaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250032578Abstract: The present invention relates to a pharmaceutical composition containing a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of thrombotic complications in a patient suffering from an acute cardiovascular event, and fulfilling at least one of the following criteria (i) to (v): (i) a degree of carotid stenosis of at least 50% as defined by NASCET criteria or at least 70% as defined by ECST; (ii) no anti-platelet therapy prior to the acute cardiovascular event, (iii) revascularization procedures selected from carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAS) and thrombolysis and thrombectomy via stent retriever are indicated; (iv) revascularization procedures selected from coronary angioplasty and stenting, and coronary artery bypass grafting (Type: ApplicationFiled: May 9, 2022Publication date: January 30, 2025Applicant: advanceCOR GmbHInventors: Götz Münch, Kristin Adler, Meinrad Gawaz
-
Publication number: 20250018010Abstract: A pharmaceutical composition for parenteral application. comprising (a) more than 2.4 mg/ml of a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1; and (b) a pharmaceutically acceptable buffer, the buffer comprising (b1) a buffering component in combination with a ph adjusting agent, which is 10 mM His/HCl, and (b2) 4 percent by weight of mannitol and (b3) 2.Type: ApplicationFiled: June 10, 2022Publication date: January 16, 2025Applicant: advanceCOR GmbHInventors: Götz Münch, Kristin Adler, Meinrad Gawaz
-
Publication number: 20130130315Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.Type: ApplicationFiled: April 6, 2011Publication date: May 23, 2013Applicant: ADVANCECOR GMBHInventors: Meinrad Gawaz, Tanja Schönberger, Heidrun Degen, Götz Münch, Hans-Peter Holthoff, Andreas Bültmann, Hans-Jörg Bühring, Christoph Leder
-
Patent number: 8168160Abstract: The present invention relates to a fusion protein comprising therapeutic and diagnostic potential against chronic vascular diseases, such as atherosclerosis, a nucleic acid molecule encoding said fusion protein, a pharmaceutical and diagnostic composition which comprises the fusion protein or the nucleic acid molecule, the use of the fusion protein or the nucleic acid molecule for the production of a pharmaceutical and diagnostic composition, a method for the diagnosis of acute or chronic vascular diseases, and a method for the production of a fusion protein.Type: GrantFiled: November 17, 2008Date of Patent: May 1, 2012Assignee: Eberhard-Karls-Universität TübingenInventors: Meinrad Gawaz, Karin Daub
-
Patent number: 8119135Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.Type: GrantFiled: January 16, 2009Date of Patent: February 21, 2012Assignees: Helmhotz Zentrum Munchen, Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH), Corimmun GmbHInventors: Götz Münch, Meinrad Gawaz, Andreas Bültmann, Elisabeth Kremmer
-
Publication number: 20100068145Abstract: The present invention relates to a bispecific fusion protein, comprising (a) a first polypeptide which binds to collagen, and (b) a second polypeptide which binds to endothelial precursor cells. Also, pharmaceutical compositions are disclosed, comprising the fusion protein of the invention, as well as methods for using the fusion protein, in particular for treating or preventing lesions of vessels and tissues.Type: ApplicationFiled: August 20, 2009Publication date: March 18, 2010Applicant: Eberhard-Karls-Universitaet TuebingenInventors: Harald Langer, Meinrad Gawaz, Hans-Jorg Buhring, Thomas Skutella, Gundram Jung
-
Publication number: 20100003244Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.Type: ApplicationFiled: January 16, 2009Publication date: January 7, 2010Inventors: Gotz Munch, Meinrad Gawaz, Andreas Bultmann, Elisabeth Kremmer
-
Publication number: 20090162285Abstract: The present invention relates to a fusion protein comprising therapeutical and diagnostic potential against chronic vascular diseases, such as atherosclerosis, a nucleic acid molecule encoding said fusion protein, a pharmaceutical and diagnostic composition which comprises the fusion protein or the nucleic acid molecule, the use of the fusion protein or the nucleic acid molecule for the production of a pharmaceutical and diagnostic composition, a method for the diagnosis of acute or chronic vascular diseases, and a method for the production of a fusion protein.Type: ApplicationFiled: November 17, 2008Publication date: June 25, 2009Inventors: Meinrad Gawaz, Karin Daub
-
Publication number: 20090130021Abstract: The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.Type: ApplicationFiled: December 12, 2005Publication date: May 21, 2009Inventors: Gotz Munch, Andreas Bultmann, Oliver Vimpany Arnold Boucher, Suresh Babubhai Chahwala, Meinrad Gawaz, Martin Ungerer
-
Patent number: 7531178Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterized by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.Type: GrantFiled: December 10, 2004Date of Patent: May 12, 2009Assignee: Trigen GmbHInventors: Steffen Massberg, Meinrad Gawaz, Andreas Bültmann, Götz Münch, Martin Ungerer, Mario Peluso
-
Patent number: 7514543Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.Type: GrantFiled: June 5, 2003Date of Patent: April 7, 2009Assignee: Trigen GmbHInventors: Steffen Massberg, Meinrad Gawaz, Andreas Bültmann, Götz Münch, Martin Ungerer, Mario Peluso
-
Publication number: 20070071744Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.Type: ApplicationFiled: June 2, 2006Publication date: March 29, 2007Inventors: Gotz Munch, Meinrad Gawaz, Andreas Bultmann, Elisabeth Kremmer
-
Publication number: 20050142140Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2005Inventors: Steffen Massberg, Meinrad Gawaz, Andreas Bultmann, Gotz Munch, Martin Ungerer, Mario Peluso
-
Publication number: 20050086710Abstract: A composition is provided comprising patelets having a combination of the following modifications: a) a modification of the protein constituents of the platelets which is obtained or obtainable by genetic modification of platelet precursor cells; b) incorporation of a detectable label into said platelet; whereby the functions of modification a) and b) are mutually independent. Further, methods of determining platelet functions, notably aggregation and adhesion to endothelial cells are provided. Further, a novel method of preparing transgenic or modified platelets is provided.Type: ApplicationFiled: February 13, 2003Publication date: April 21, 2005Inventors: Mario Peluso, Martin Ungerer, Meinrad Gawaz, Steffen Massberg, Karl-Ludwig Laugwitz, Angelika Gillitzer
-
Publication number: 20050079541Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.Type: ApplicationFiled: June 5, 2003Publication date: April 14, 2005Inventors: Steffen Massberg, Meinrad Gawaz, Andreas Bultmann, Gotz Munch, Martin Ungerer, Mario Peluso
-
Publication number: 20040241166Abstract: The invention relates to the use of an IKK-&bgr; inhibitor for the production of a medicament for the treatment or prevention of atheroscieroses. A screening method for the discovery of IKK-&bgr; inhibitors in endothelial cells is also disclosed. The method involves the contacting of a potential inhibitor with activated endothelial cells and a determination of the secretion of MCP-1 from the endothelial cells.Type: ApplicationFiled: July 6, 2004Publication date: December 2, 2004Inventors: Martin Ungerer, Korbinian Brand, Meinrad Gawaz
-
Publication number: 20040029775Abstract: The invention relates to the use of &bgr;3-endonexin-long or &bgr;3-endonexin-short for finding active substances for the treatment of arteriosclerosis, unstable plaques resulting from the latter, acute coronary thrombosis, cardiac infarct, stroke, peripheral arterial occlusion diseases, chronic venous ulcer and restenosing processes.Type: ApplicationFiled: July 1, 2003Publication date: February 12, 2004Inventors: Meinrad Gawaz, Martin Ungerer, Waldemar Kolanus